Publicaciones científicas

Phase I Open Label Liver-Directed Gene Therapy Clinical Trial for Acute Intermittent Porphyria

D'Avola D (1), López-Franco E (2), Sangro B (1), Pañeda A (3), Grossios N (4), Gil-Farina I (5), Benito A (6), Twisk J (4), Paz M (3), Ruiz J (3), Schmidt M (5), Petry H (4), Harper P (7), de Salamanca RE (8), Fontanellas A (9), Prieto J (10), González-Aseguinolaza G (11).
(1) Liver Unit, Clínica Universidad de Navarra, Avda. Pio XII 36, Pamplona 31008, Spain; Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (Ciberehd), Liver Unit, Clínica Universidad de Navarra, Avda. Pio XII 36, Pamplona 31008, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Calle Irunlarrea 3, Pamplona 31008, Spain.
(2) Gene therapy and regulation of Gene Expression Program. Centro de Investigación Médica Aplicada. Universidad de Navarra. Avda. Pio XII 55, Pamplona 31008, Spain.
(3) DIGNA BIOTECH S.L. C/Boix y Morer 6-8°, Madrid 28003, Spain.
(4) UniQure biopharma B.V., Meibegdreef 61, 1105 BA Amsterdam, The Netherlands.
(5) National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
(6) Radiology, Clínica Universidad de Navarra, Avda. Pio XII 36, Pamplona 31008, Spain.
(7) Porphyria Centre Sweden, Karolinska University Hospital, Stockholm Sweden.
(8) Centro de Investigación del Hospital Universitario 12 de Octubre. Avda. de Cordoba Km 54, Madrid 28041, Spain.
(9) Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (Ciberehd), Liver Unit, Clínica Universidad de Navarra, Avda. Pio XII 36, Pamplona 31008, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Calle Irunlarrea 3, Pamplona 31008, Spain; Hepatology Program, Centro de Investigación Médica Aplicada. Universidad de Navarra. Avda. Pio XII 55, Pamplona 31008, Spain.
(10) Liver Unit, Clínica Universidad de Navarra, Avda. Pio XII 36, Pamplona 31008, Spain; Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (Ciberehd), Liver Unit, Clínica Universidad de Navarra, Avda. Pio XII 36, Pamplona 31008, Spain; Gene therapy and regulation of Gene Expression Program. Centro de Investigación Médica Aplicada. Universidad de Navarra. Avda. Pio XII 55, Pamplona 31008, Spain.
(11) Instituto de Investigación Sanitaria de Navarra (IdiSNA), Calle Irunlarrea 3, Pamplona 31008, Spain; Gene therapy and regulation of Gene Expression Program. Centro de Investigación Médica Aplicada. Universidad de Navarra. Avda. Pio XII 55, Pamplona 31008, Spain 

Revista: Journal of Hepatology

Fecha: 17-may-2016

Hepatología

BACKGROUND & AIMS:

Acute intermittent porphyria (AIP) results from porphobilinogen deaminase (PBGD) haploinsufficiency, which leads to hepatic over-production of the neurotoxic heme precursors porphobilinogen (PBG) and delta-aminolevulinic acid (ALA) and the occurrence of neurovisceral attacks.

Severe AIP is a devastating disease that can only be corrected by liver transplantation. Gene therapy represents a promising curative option. The objective of this study was to investigate the safety of a recombinant adeno-associated vector expressing PBGD (rAAV2/5-PBGD) administered for the first time in humans for the treatment of AIP.

METHODS

In this phase I, open label, dose-escalation, multicenter clinical trial, four cohorts of 2 patients each received a single intravenous injection of the vector ranging from 5x1011 to 1.8x1013 genome copies/kg.

Adverse events and changes in urinary PBG and ALA and in the clinical course of the disease were periodically evaluated prior and after treatment. Viral shedding, immune response against the vector and vector persistence in the liver were investigated.

RESULTS

Treatment was safe in all cases. All patients developed anti-AAV5 neutralizing antibodies but no cellular responses against AAV5 or PBGD were observed. There was a trend towards a reduction of hospitalizations and heme treatments, although ALA and PBG levels remained unchanged. Vector genomes and transgene expression could be detected in the liver one year after therapy.

CONCLUSION

rAAV2/5-PBGD administration is safe but AIP metabolic correction was not achieved at the doses tested in this trial. Notwithstanding, the treatment had a positive impact in clinical outcomes in most patients.

LAY SUMMARY

Studies in an acute intermittent porphyria (AIP) animal model have shown that gene delivery of PBGD to hepatocytes using an adenoassociated virus vector (rAAV2/5-PBG) prevent mice from suffering porphyria acute attacks.

In this phase I, open label, dose-escalation, multicenter clinical trial we show that the administration of rAAV2/5-PBGD to patients with severe AIP is safe but metabolic correction was not achieved at the doses tested; the treatment, however, had a positive but heterogeneous impact on clinical outcomes among treated patients and 2 out of 8 patients have stopped hematin treatment.

CITA DEL ARTÍCULO  J Hepatol. 2016 May 17. pii: S0168-8278(16)30198-2. doi: 10.1016/j.jhep.2016.05.012

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra